Format

Send to

Choose Destination
Vaccine. 2005 Mar 18;23(17-18):2030-4.

DermaVir, a novel HIV immunisation technology.

Author information

1
Research Institute for Genetic and Human Therapy, 2233 Wisconsin Ave. Suite 503, Washington, DC 20007, USA. rightpv@tin.it

Abstract

DermaVir is a novel topical immunisation designed to target Langerhans cells (LC), the epidermal precursors of dendritic cells. LC serve as a vehicle to process and transfer antigens from the skin to T cell areas in the lymphoid organs. The HIV DNA delivered by DermaVir to LC expresses most viral regulatory and structural genes and induces T cell-mediated immune responses with broad specificity. In chronically infected macaques, DermaVir administered with antiretroviral drugs, suppressed viral load rebound after treatment interruption and improved survival. DermaVir is a promising antiretroviral treatment approach with a unique mechanism of action for combination with currently used drugs.

PMID:
15755566
DOI:
10.1016/j.vaccine.2005.01.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center